In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...

On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...

Warning! GuruFocus has detected 6 Warning Signs with RVMD. Revolution Medicines Inc (NASDAQ:RVMD), a clinical-stage precision ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.66% ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...

Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its ...

Good day and thank you for standing by. Welcome to Revolution Medicine’s Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s ...

Below is Validea's guru fundamental report for REVOLUTION MEDICINES INC (RVMD). Of the 22 guru strategies we follow, RVMD rates highest using our Quantitative Momentum Investor model based on the ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $82 from $72 and keeps a Buy rating on the shares after the company presented initial Phase 1 ...

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its target price upped by research analysts at Guggenheim from $72.00 to $82.00 in a note issued to investors on Monday, Benzinga reports.